Acute Valve Syndrome in Aortic Stenosis

“These findings are extremely important and complementary to the recently presented EARLY TAVR Trial, published in the NEJM. The absence of symptoms was traditionally considered a sign of relative safety. However, this study shows how frequent acute valve syndrome is in patients undergoing AVR, and how patients would benefit greatly from intervention before symptoms appear.”

Philippe Généreux, MD, FACC Director of the Structural Heart Program at Morristown Medical Center’s Gagnon Cardiovascular Institute and lead author of the study.

AIM

To describe the impact of clinical presentation among patients with aortic stenosis (AS) undergoing aortic valve replacement (AVR).

METHODS & RESULTS

We analyzed a de-identified real-world dataset including patients from 29 US hospitals with appropriate permissions (egnite Database, egnite). Patients >18 years old with moderate or greater AS undergoing AVR were included. Patients were classified in 3 groups according to the acuity and severity of clinical presentation prior to AVR: (i) asymptomatic, (ii) progressive signs and symptoms (progressive valve syndrome [PVS]), and (iii) acute or advanced signs and symptoms (acute valve syndrome [AVS]). Mortality and heart failure hospitalization after AVR were examined with Kaplan–Meier estimates, with results compared using the log-rank test.

Among 2,009,607 patients in our database, 17,838 underwent AVR (78.6% transcatheter AVR, 21.4% surgical AVR). Age was 76.5±9.7 years, and 40.2% were female. Prior to AVR, 2504 (14.0%) were asymptomatic, 6116 (34.3%) presented with PVS, and 9218 (51.7%) presented with AVS. At two years, the estimated rate of mortality for asymptomatic, PVS, and AVS were 5.8% (4.6%-7.0%), 7.6% (6.7%-8.4%), 17.5% (16.5%-18.5%), respectively, and the estimated rate of hospitalization with heart failure for asymptomatic, PVS, and AVS were 11.1% (9.5%-12.6%), 19.0% (17.8%-20.2%), 41.5% (40.2%-42.8%). After adjustment, patients presenting with AVS had increased risk of mortality after AVR (hazard ratio, 2.2; 95% CI, 1.8-2.6).

CONCLUSIONS

From a large, real-world database of patients undergoing AVR for AS, most patients presented with AVS, which was associated with an increased risk of mortality and heart failure hospitalization.

*This study is part of egnite’s cardiovascular real-world evidence bibliography, which lists all of our peer-reviewed articles, conference abstracts, and patents.

Follow egnite on social:

Related Articles

egnite Research

Why Real-World Evidence Matters: Closing the Data Gap on M-TEER Durability

Real-world evidence (RWE) has become one of the most important tools in clinical research because it shows how therapies perform in everyday practice, across broad populations and over many years. But not all real-world data is built to answer every question. Few areas show the need for real-world evidence more

Moderate AS patients outnumbered severe AS by nearly 2:1
egnite Research

Moderate Aortic Stenosis (AS) With At-Risk Features

ACTIVATE AS is a prospective, multicenter observational study using the CardioCare® platform to identify and follow patients with moderate AS. Participants receive heart team evaluation, core lab echo, natriuretic peptide testing and CT calcium scoring. Enrollment is expected to begin in 2027.

egnite 2026 benchmark report
egnite Research

The egnite 2026 Benchmark Report

The report tracks heart failure and structural heart care across 47 U.S. health systems, 830 facilities, and more than 15.7 million de-identified patients. Read the full report.